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xtracellular stimuli that activate cell surface receptors
modulate glucocorticoid actions via as yet unclear
mechanisms. Here, we report that the guanine
nucleotide-binding protein (G protein)–coupled receptor-
activated WD-repeat G
 
 
 
 interacts with the glucocorticoid
receptor (GR), comigrates with it into the nucleus and
suppresses GR-induced transactivation of the glucocorticoid-
responsive genes. Association of G
 
 
 
 with G
 
 
 
 is necessary
for this action of G
 
 
 
. Both endogenous and enhanced
green ﬂuorescent protein (EGFP)–fused G
 
 
 
2 and G
 
 
 
2
proteins were detected in the nucleus at baseline, whereas
E
 
a fraction of EGFP-G
 
 
 
2 and DsRed2-GR comigrated
to the nucleus or the plasma membrane, depending on
the exposure of cells to dexamethasone or somatostatin,
respectively. G
 
 
 
2 was associated with GR/glucocorti-
coid response elements (GREs) in vivo and suppressed
activation function-2–directed transcriptional activity of
the GR. We conclude that the G
 
  
 
 complex interacts
with the GR and suppresses its transcriptional activity
by associating with the transcriptional complex formed
on GR-responsive promoters.
 
Introduction
 
Glucocorticoids play a crucial role in the regulation of basal
and stress-related homeostasis. They are necessary for mainte-
nance of many important biological activities, such as the
homeostasis of the central nervous and cardiovascular systems,
the intermediary metabolism and the immune/inflammatory
reaction (Chrousos, 2004). They also act as potent immuno-
suppressive and anti-inflammatory agents at “pharmacologic”
doses, properties that make them irreplaceable therapeutic
means for many inflammatory, autoimmune, allergic, and
lymphoproliferative diseases (Kino et al., 2003a).
The actions of glucocorticoids are mediated by a ubiquitous
intracellular receptor protein, the glucocorticoid receptor (GR),
which functions as a hormone-activated transcription factor of
glucocorticoid target genes (Kino et al., 2003a). The GR
consists of three domains: the NH
 
2
 
-terminal or “immunogenic”
domain, the central, DNA-binding domain (DBD), and the
COOH-terminal, ligand-binding domain. The functions of the
latter two domains have been studied extensively, whereas
those of the immunogenic domain are less well known (Kino et
al., 2003a). In the unliganded state, GR is located primarily in
the cytoplasm, as part of hetero-oligomeric complexes containing
heat shock proteins 90, 70, and 50, and, possibly, other proteins.
After binding to its agonist ligand, the GR undergoes confor-
mational changes, dissociates from the heat shock proteins,
homodimerizes, and translocates into the nucleus through the
nuclear pore via an active process (Kino et al., 2003a).
There, the ligand-activated GR directly interacts with DNA
sequences, the glucocorticoid response elements (GREs), in the
promoter regions of target genes, or with other transcription
factors via protein–protein interactions, indirectly influencing
the activity of the latter on their target genes (Kino and Chrousos,
2002; Kino et al., 2003a). The GRE-bound GR stimulates the
transcription rate of responsive genes by facilitating the formation
of a transcription initiation complex, including the RNA
polymerase II and its ancillary components via its activation
function (AF)-1 and AF-2 domains (Kino et al., 2003a). The
former is localized in the immunogenic domain, whereas the
latter spans the entire ligand-binding domain.
Because glucocorticoids have a broad array of life-sus-
taining functions and play an important role in therapeutic
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interventions, changes of tissue sensitivity to glucocorticoids
may be associated with and influence the course and therapy of
many pathological states (Kino and Chrousos, 2002; Kino et
al., 2003a). Such changes may present on either side of an opti-
mal range, respectively, as glucocorticoid resistance or hypersen-
sitivity, and may be generalized and/or tissue specific. Several
autoimmune/inflammatory/allergic states, such as rheumatoid
arthritis, osteoarthritis, Crohn’s disease, ulcerative colitis and
asthma, are often associated with resistance of the inflamed tis-
sues to glucocorticoids (Chrousos, 1995; Kino and Chrousos,
2002). On the other hand, glucocorticoid hypersensitivity has
been suggested in visceral obesity–related insulin resistance as-
sociated with components of the dysmetabolic syndrome, and
in the acquired immunodeficiency syndrome caused by human
immunodeficiency virus type 1 infection (Chrousos, 2000;
Kino et al., 2003b). These changes in tissues’ sensitivity to glu-
cocorticoids associated with such pathological conditions may
be possible by local modifications of GR functions, where al-
tered concentrations/production of hormones, neurotransmit-
ters, cytokines, growth factors and autacoids may play impor-
tant roles (Kino and Chrousos, 2002; Kino et al., 2003a). The
biological activities of such extracellular molecules are trans-
duced into the intracellular compartment via their specific cell
surface receptors (Cotecchia et al., 2004; Radeff-Huang et al.,
2004). Binding of the compounds to their receptors activates
signal-transducing molecules located on the cytoplasmic side
of the plasma membrane, which subsequently communicate
with downstream effector molecules, finally exerting a variety
of biological effects on their target cells.
The heterotrimeric guanine nucleotide-binding proteins
(G proteins) are downstream signal transducers for the G protein–
coupled receptors (GPCRs), which form a large family consist-
ing of 
 
 
 
1,000 members (Cabrera-Vera et al., 2003). There are
three subunits, G
 
 
 
, G
 
 
 
, and G
 
 
 
, each of which is also com-
posed of many isoforms (Hamm, 1998; Cabrera-Vera et al.,
2003). Among them, G
 
 
 
 contains a portion characterized as a
seven times–repeated blade-like structure, called a WD repeat
(Clapham and Neer, 1997; Smith et al., 1999). Crystallographic
analyses revealed that all WD-repeats of G
 
 
 
 are made up of
four twisted 
 
 
 
 strands and are arranged in a ring, thus, forming
a propeller-like structure (Clapham and Neer, 1997). G
 
 
 
 is as-
sociated with G
 
 
 
 through its NH
 
2
 
-terminal 
 
 
 
 helical portion
and the fifth blade of the WD repeats.
The heterotrimeric complex consisting of G
 
 
 
, G
 
 
 
, and G
 
 
 
is attached to the cytoplasmic surface of the plasma membrane
through the prenylated G
 
 
 
 (Clapham and Neer, 1997). This het-
erotrimeric complex is inactive in the GDP-bound state. Once
ligands bind to their GPCRs, GDP on G
 
 
 
 is catalyzed to GTP,
leading to dissociation of the GTP-bound G
 
 
 
 from the G
 
 
 
/G
 
 
 
heterodimer (Hamm, 1998). Liberated GTP-G
 
 
 
 and the G
 
 
 
/G
 
 
 
complex then interact with their downstream effector molecules
and exert their biological actions (Clapham and Neer, 1997).
The G
 
 
 
/G
 
 
 
 complex binds to and modulates the activity of
diverse molecules, such as several forms of potassium and
calcium ion channels, the enzymes phospholipase A2 and C
 
 
 
,
several adenylyl cyclases and the plasma membrane Ca
 
2
 
 
 
ATPase pump (Clapham and Neer, 1997).
The receptor for activated C-kinase 1 (Rack1), also a
WD-repeat protein that harbors 42% amino acid similarity to
G
 
 
 
 with many conserved amino acids, plays regulatory roles in
cell development and growth, as well as in the immune re-
sponse and brain function (McCahill et al., 2002). Rack1 exerts
its biological activities by binding to numerous partner mole-
cules, including PKCb, phosphodiesterase 4-D5, Src family ki-
nases, the Interleukin-3 and Interleukin-5, and granulocyte
macrophage-colony stimulating factor receptors, and by regu-
lating their activities as a scaffold molecule providing steric
hindrance (McCahill et al., 2002). For example, Rack1 acts as a
negative scaffold on the Src family kinases by binding to the
phosphotyrosine-binding pocket of their Src homology-2 do-
mains and by inhibiting their further association with down-
stream molecules (Chang et al., 2001; McCahill et al., 2002).
To look for partner molecules that may interact with GR
and explain the local modification of GR activity in several phys-
iological or pathological conditions, we performed a yeast two-
hybrid screening assay using fragments of the GR immunogenic
domain. We found that the WD repeat proteins G
 
 
 
2 and Rack1
are specific interactors of GR, negatively regulating its transcrip-
tional activity. Because G
 
 
 
 proteins play key roles in many sig-
nal transduction cascades, GR-associated G
 
 
 
 might play a role in
the development of target tissue resistance or hypersensitivity to
glucocorticoids in states in which the G protein system is af-
fected and the sensitivity to glucocorticoids is altered.
 
Results
 
G
 
 
 
1, G
 
 
 
2, and Rack1, all interact with 
GR(263-419)
 
The immunogenic domain of the human GR consists of 420 aa
accounts for over a half of the entire molecule. Although it con-
tains the AF-1 domain at amino acid positions 77–261, through
which the GR communicates with components of the transcrip-
tional machinery, the functions of the rest of the immunogenic
domain are yet unknown. We performed a yeast two-hybrid screen-
ing assay using as bait a GR fragment spanning amino acids 263–
419, located between the AF-1 domain and the DBD in a Jurkat
cDNA library. Among over 85 independent interactors, we found
two independent clones, which contained the COOH-terminal
half of the human G
 
 
 
2 and Rack1 coding sequences, respectively
(unpublished data). We confirmed the binding of GR(263-419) to
full-length G
 
 
 
2, as well as its close isoform G
 
 
 
1, and Rack1, in a
reconstituted yeast two-hybrid assay (Fig. 1). As expected, full-
length G
 
 
 
1, G
 
 
 
2, and Rack1 all interacted with GR(263-419) in
this system. Rack1(139-317), which spans blades 4–7 of Rack1,
was also associated with this fragment of the GR (Fig. 1 A). To
map the portion of G
 
 
 
2, which was responsible for binding to
GR, we constructed a series of plasmids expressing the B42-acti-
vation domain fusions of the G
 
 
 
2 fragments, and examined their
interactions to GR(263-419) fused to the LexA-DBD in the same
yeast two-hybrid assay (Fig. 1 B). We found that amino acids
143–270 of G
 
 
 
2, which correspond to blades 3–5 of G
 
 
 
2, sup-
ported the interaction between G
 
 
 
2 and GR(263-419). A sum-
mary of the yeast two-hybrid assays examining the interactions of
G
 
 
 
2 and Rack1 with GR(263-419) is shown in Fig. 1 C. 
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G
 
 
 
s suppress the transcriptional activity 
of GR
 
We next examined the effect of G
 
 
 
1, 2, and Rack1 on GR-
induced transcriptional activity of the glucocorticoid-respon-
sive mouse mammary tumor virus (MMTV) promoter in
HCT116 cells (Fig. 2 A). Overexpression of these molecules
dose-dependently suppressed the transcriptional activity of
GR. Because G
 
 
 
2 showed the strongest suppressive effect,
we focused on G
 
 
 
2 in further functional analyses. G
 
 
 
2
strongly suppressed the transcriptional activity of the wild-
type GR, whereas it lost its suppressive effect on GR(
 
 
 
262-
404), which is devoid of an interaction domain for G
 
 
 
2 (Fig.
2 B). Indeed, this GR deletion mutant demonstrated stronger
transcriptional activity on the MMTV promoter than the wild-
type GR, suggesting that endogenously expressed G
 
 
 
, Rack1,
and/or other related molecules might down-regulate the tran-
scriptional activity of the wild-type GR by physical associa-
tion through this portion of GR. We also tested G
 
 
 
2 on the
dexamethasone titration curve of the luciferase activity from
the MMTV promoter-driven luciferase gene in HCT116 cells
(Fig. 2 C). Overexpression of G
 
 
 
2 dramatically shifted the ti-
tration curve downward, indicating that G
 
 
 
2 suppressed GR-
induced transactivation by acting at a step subsequent to
ligand binding of the GR.
We also tested G
 
 
 
 activity on a well-known endogenous
glucocorticoid-responsive gene, the rat tyrosine aminotrans-
ferase (TAT). Glucocorticoids increase TAT enzymatic activ-
ity by stimulating the transcriptional rate of its gene via tandem
GREs located in the promoter region (Thompson et al., 1966;
Jantzen et al., 1987). In rat HTC cells, 10
 
 
 
6
 
 M of dexametha-
sone increased TAT activity by fivefold, whereas transfection
of short interfering RNAs (siRNAs) for G
 
 
 
1 and G
 
 
 
2 signifi-
cantly enhanced dexamethasone-stimulated TAT activity (Fig.
2 D). These siRNAs reduced mRNA abundance of G
 
 
 
1 and
G
 
 
 
2 (Fig. 2 E) and their protein levels (Fig. 2 F). These results
indicate that endogenous G
 
 
 
1 and G
 
 
 
2 act as negative regula-
tors of GR transactivation on an endogenous glucocorticoid-
responsive gene.
 
The G
 
 
 
/G
 
 
 
 heterodimer, but not G
 
 
 
i, 
is associated with GR in vivo
 
To test if G
 
 
 
 interacts with GR in vivo, we performed a regular
coimmunoprecipitation assay using specific antibodies to G
 
 
 
,
G
 
 
 
, G
 
 
 
i, and GR in HeLa cells, which express all these mole-
cules endogenously. Both G
 
 
 
 and G
 
 
 
, but not G
 
 
 
i, were copre-
cipitated with GR in the absence of dexamethasone, and addi-
tion of dexamethasone increased the precipitation of these
molecules with GR (Fig. 2 G, top three gels). This effect of
dexamethasone was not through induction of any of these three
proteins, because their expression levels did not change
throughout the experiment (Fig. 2 G, bottom four gels). These
results indicate that the G
 
 
 
/G
 
 
 
 heterodimer, but not G
 
 
 
i, is a
component of the complex formed with GR both in the absence
and presence of glucocorticoids. G
 
 
 
2 mutants, G10K and
G
 
 
 
2(34–340), both of which are defective in the association
with G
 
 
 
 (Garritsen et al., 1993), lost the wild-type G
 
 
 
 suppres-
sive effect on GR-induced transactivation in HCT116 cells (un-
published data), further confirming that G
 
 
 
2 acts as a het-
erodimer with G
 
 
 
 to suppress the transcriptional activity of the
GR. They also suggest that the overexpressed G
 
 
 
1 and G
 
 
 
2
acted on GR by forming complexes with endogenous G
 
 .
Somatostatin suppresses GR-induced 
transcriptional activity by activating 
G /G  in rat GH3 cells
Somatostatin binds its receptor and activates the G /G  dimer
by causing dissociation of the complex from GTP-bound G i
(Law et al., 1991; Brown and Schonbrunn, 1993). Thus, we
tested the effect of somatostatin on GR-induced transactivation
in rat pituitary GH3 cells, which express endogenous somato-
statin receptor and GR (Yatani et al., 1987; Levitan et al., 1991).
These cells also express the Kv1.5 potassium channel, whose
expression levels are positively regulated by glucocorticoids
possibly though GREs located in its promoter region (Levitan et
al., 1991). 24-h incubation of cells with 10
 6 M of dexametha-
sone stimulated mRNA expression of the Kv1.5 potassium
channel by eightfold and somatostatin suppressed this dexa-
Figure 1. G 1, G 2 and Rack1 interact
with GR(263-419) in yeast two-hybrid assays.
(A) Full-length G 1, G 2, and Rack1, as well
as Rack1(139-317) interact with GR(263-
420) in a yeast two-hybrid assay. EGY48
yeast cells were transformed with p8OP-LacZ,
pLexA-GR (263-419) and the indicated full-
length G 1-, G 2-, Rack1-, or Rack1(139-
317)-expressing pB42AD-derived plasmids.
Bars represent mean   SEM values of fold
activation compared with the baseline. (B)
G 2(143-270) (blades 3–5) interacts with
GR(263-420) in a yeast two-hybrid assay.
EGY48 yeast cells were transformed with
p8OP-LacZ, pLexA-GR (263-419) and the
indicated G 2 fragment-expressing pB42AD
plasmids. Bars represent mean   SEM values
of fold activation compared with the baseline.
(C) Summary of yeast two-hybrid assays,
which demonstrates domains of G 2 and
Rack1 that are necessary for the interaction
with GR(263-419).JCB • VOLUME 169 • NUMBER 6 • 2005 888
methasone effect in a dose-dependent fashion (Fig. 3 A). Trans-
fection of G 1 and G 2 siRNAs, which strongly suppressed the
mRNA expression of these subunits (Fig. 3, B and C), enhanced
dexamethasone-induced induction of Kv1.5 potassium channel
mRNA and attenuated the suppressive effect of somatostatin
(Fig. 3 A). These results indicate that somatostatin suppressed
GR-induced transcriptional activity of the endogenous Kv1.5
potassium channel gene by activating the G /G  complex.
G 2 and G 2 are localized in the nucleus 
and G 2 translocates into the nucleus 
with GR
The trimeric G protein complexes are presumably exclu-
sively located in the cytoplasmic surface of the plasma
membrane in order to serve as intermediate communicators
between membrane-integrated GPCRs and their downstream
effector molecules (Clapham and Neer, 1997). G  plays a
central role in anchoring the G protein complexes on the
plasma membrane through a prenylated cysteine residue lo-
cated amino acid 68 (in a CAAX motif; Clapham and Neer,
1997). Small amounts of G protein are also detected in cave-
olae, growth cones and cytoskeleton (Clapham and Neer,
1997). In contrast, GR is located in the cytoplasm in the ab-
sence of ligands and translocates into the nucleus in re-
sponse to ligand binding (Kino et al., 2003a). The discrep-
ancy in the subcellular localization of G /G  and GR
prompted us to examine the subcellular distribution of G 
and G  (Fig. 4).
Figure 2. G 1, G 2, and Rack1 suppress
the transcriptional activity of GR on the MMTV
promoter, and endogenous G  and G  are
associated with GR in vivo. (A) G 1, G 2,
and Rack1 dose dependently suppress the
transcriptional activity of GR on the MMTV
promoter in HCT116 cells. HCT116 cells were
transfected with indicated amounts of G 1,
G 2, or Rack1-expressing plasmids together
with pRShGR , pMMTV-Luc, and pSV40- -
Gal. Bars represent mean   SEM values of
the luciferase activity normalized for  -galac-
tosidase activity in the absence or presence of
10
 6 M of dexamethasone. (B) GR( 262-
404) has stronger transcriptional activity than
the wild-type GR and G 2 loses its suppres-
sive effect on GR( 262-404)-induced transac-
tivation in HCT116 cells. HCT116 cells were
transfected with G 2-expressing plasmids and
pRShGR  or pRShGR ( 262-404), together
with pMMTV-Luc and pSV40- -Gal. Bars
represent mean   SEM values of the luciferase
activity normalized for  -galactosidase activity
in the absence or presence of 10
 6 M of
dexamethasone. (*), P   0.01; n.s., not signifi-
cant, compared with the baseline. (C) Expres-
sion of G 2 shifts the dexamethasone titration
curve of the luciferase activity from the pM-
MTV-Luc in HCT116 cells. HCT116 cells were
transfected with pRShGR , pMMTV-Luc, and
pSV40- -Gal in the absence or presence of
G 2-expressing plasmid. Cells were then
stimulated with increasing concentrations of
dexamethasone. Open and closed circles
represent mean   SEM values of the luciferase
activity normalized for  -galactosidase activity
in the absence (open circle) or presence
(closed circle) of the G 2 expression. (D–F)
Abrogation of G 1 and G 2 enhanced dexa-
methasone-activated TAT activity (D) and
suppressed mRNA (E) and protein (F) levels of
G 1 and G 2 in HTC cells. HTC cells were
transfected with control or G 1 and G 2
siRNAs and the cells were treated with 10
 6 M
of dexamethasone for 24 h. Cell lysate and to-
tal RNA were harvested and the TAT activity
(D), G 1 and G 2 mRNA abundance (E) and
protein levels of G 1 and G 2 in Western
blots using their specific antibodies in the
absence of dexamethasone (F), were determined. Bars represent mean   SEM values of TAT activity (D) or fold induction of G 1 or G 2 mRNAs (E) in the
absence or presence of 10
 6 M of dexamethasone. (*), P   0.01; n.s., not significant, compared with the baseline. (G) Endogenous G  and G , but not
G i, are associated with GR in vivo. HeLa cells were stimulated with 10
 6 M of dexamethasone and coimmunoprecipitation was performed with control
or anti-GR  antibody. After blotting the precipitated proteins on nitrocellulose membranes, the associated G , G , or G i was detected with their specific
antibodies. Expression of G , G , G i, and GR was also examined in 10% whole homogenates in Western blots.INTERACTION OF G PROTEIN   AND GR • KINO ET AL. 889
We first examined the localization of endogenous G 
and G  in HCT116 cells by using specific antibodies in indi-
rect immunofluorescent staining studies. The majority of en-
dogenous G  and G  molecules were localized in the cyto-
plasm, however small fractions were also detected in the
plasma membrane and the nucleus (Fig. 4 A, top). In some
cells, both G  and G  were localized exclusively in the cyto-
plasm (cell “ℵ” and “a”), whereas other cells retained these
molecules weakly (cell “ℑ” and “b”) or strongly (cell “ℜ” and
“c”) in the nucleus (Fig. 4 A, middle). Treatment of the cells
with blocking peptides in addition to their antibodies, com-
pletely abolished these specific staining patterns (Fig. 4 A,
bottom). In Western blots, G  and G  were also detected in
the cytoplasmic and nuclear fractions, as well as in the mem-
brane fraction (Fig. 4 B).
To further examine the subcellular localization of G  and
G , we constructed plasmids expressing EGFP-fused G 2 or
G 2 and examined their localization in the HCT116 cells (Fig.
4, C and D). Consistent with our results obtained with indirect
immunofluorescence staining and Western blots, EGFP-G 2
was mainly distributed in the cytoplasm, with a relatively small
fraction in the nucleus and a very small fraction at the plasma
membrane (Fig. 4 C, left and Fig. 4 D). EGFP-G 2 was also
detected in the cytoplasm, as well as at the plasma membrane,
whereas a small fraction was detected in the nucleus (Fig. 4 C,
right, and Fig. 4 D). The limited localization of EGFP-G 2 at
the plasma membrane was not caused by a small number of
binding sites at the plasma membrane, as coexpression of G 2
and the human somatostatin receptor type 2 (SSTR2) that pro-
vided binding sites for EGFP-G 2 at the plasma membrane,
did not change the characteristic subcellular localization of
EGFP-G 2 (unpublished data).
G 2 and GR comigrate either to the 
nucleus or to the plasma membrane in 
response to dexamethasone or 
somatostatin, respectively
Because the above results suggest that G 2 and GR might
communicate in the cytoplasm as well as in the nucleus, we
examined colocalization of these two molecules by overex-
pressing EGFP-G 2 and DsRed2-GR in HCT116 cells (Fig.
4, E and F). EGFP-G 2 was localized mainly in the cyto-
plasm in addition to the nucleus, whereas DsRed2-GR was
exclusively distributed in the former subcellular fraction in
the absence of glucocorticoids. 30-min incubation of the
transfected cells with 10
 6 M of dexamethasone induced nu-
clear translocation of both DsRed2-GR and EGFP-G 2 (Fig.
4, E and F).
Because very little G 2 was found at the plasma mem-
brane and EGFP-G 2 comigrated from the cytoplasm into
the nucleus with the GR in response to dexamethasone, we
stimulated a GPCR to test the hypothesis that this treatment
induces the plasma membrane localization of EGFP-G  in
HCT116 cells. We coexpressed EGFP-G 2 and DsRed2-GR
with G 2 and SSTR2, added 100 nM of somatostatin in the
medium and examined the localization of EGFP-G 2 under
the microscope. 30 min after addition of somatostatin,
EGFP-G 2 accumulated at the plasma membrane (Fig. 4
G). EGFP-G 2 was not seen at the plasma membrane after
3 h, possibly because of internalization of the receptor com-
plex into the cell (unpublished data). As expected, a small
amount of DsRed2-GR also accumulated at the plasma
membrane with EGFP-G 2. These results indicate that
EGFP-G 2 migrated from the cytoplasm to the plasma
membrane in response to stimulation of a G protein–cou-
pled, cell surface receptor. They also indicate that some
fractions of G  and GR are associated with each other in the
cytoplasm and can translocate to either the nucleus or the
plasma membrane following the activation of the GR or the cell
surface GPCR.
Figure 3. Somatostatin suppressed dexamethasone-stimulated transcrip-
tional activity of the Kv1.5 potassium channel gene, whereas abrogation
of G 1 and G 2 attenuated the somatostatin effect in GH3 cells. GH3
cells were transfected with control or G 1 and G 2 siRNAs, and were
treated with 10
 6 M of dexamethasone and/or the indicated amounts of
somatostatin for 24 h. Total RNA was then purified from the cells and the
amounts of Kv1.5 potassium channel (A), G 1 (B), G 2 (C), or RPLP0
mRNAs were determined by RT-PCR. Bars show mean   SEM of their fold
induction over baseline.JCB • VOLUME 169 • NUMBER 6 • 2005 890
Figure 4. Subcellular localization of G 2 and G 2 in HCT116 cells. (A) Endogenous G  and G  are visualized in the nucleus as well as in the cytoplasm/
plasma membrane in HCT116 cells. Endogenous G  (left, top two panels) and G  (right, top two panels) were visualized by treatment with anti-G  or -G 2
antibodies, and FITC-labeled secondary antibody, and their confocal images were obtained. Nuclei were also stained with DAPI. Co-treatment of the
samples with blocking peptides for anti-G  (left, bottom) or anti-G 2 (right, bottom) antibodies abolished their specific staining. Cells, expressing G  or G 
exclusively in the cytoplasm, are indicated as “ℵ” and “a”, respectively, whereas cells retaining these molecules weakly or strongly in the nucleus are
indicated as “ℑ” and “b”, and “ℜ” and “c”, respectively. (B) Endogenous G  and G  are detected in the nuclear fraction as well as in the cytoplasm and
membrane fractions in HCT116 cells. HCT116 cells were lysed and their subcellular fractions were separated by centrifugation. 0.1  g of protein of
indicated subcellular fractions was run on SDS-PAGE gels, blotted to the nitrocellulose membranes, and G  and G  were visualized with their specific
antibodies by reprobing the same membrane. Intracellular adhesion molecule 1 (ICAM1),  -tubulin, and Oct1, detected also by reprobing the same
membrane with their specific antibodies, were respectively shown as positive controls for the membrane, cytoplasmic and nuclear fractions to indicate that
the subcellular fractionation did not produce cross-contamination. (C and D) EGFP-G 2 was localized in the nucleus in addition to the cytoplasm, whereas
EGFP-G 2 was detected in the nucleus and the cytoplasm, and at the plasma membrane in HCT116 cells. HCT116 cells were transfected with pEGFP-C-1-G 2INTERACTION OF G PROTEIN   AND GR • KINO ET AL. 891
Forced cytoplasmic localization of G 2 
attenuates its suppressive effect on GR-
induced transcriptional activity
To further examine the mechanism of G 2-induced suppression
of GR transactivation, we constructed plasmids expressing a nu-
clear export signal (NES)- or NLS-fused G 2 and EGFP-G 2.
The NES sequence used was that of the human protein kinase in-
hibitor   (Henderson and Eleftheriou, 2000), whereas the NLS
sequence was from the SV40 large T antigen (Rihs et al., 1991).
NES-fused EGFP-G 2 was localized exclusively in the cyto-
plasm, whereas NLS-fused EGFP-G 2 was located entirely in
the nucleus (Fig. 5, A and B). As expected, NES-G 2 lost its sup-
pressive effect on GR-induced transactivation, whereas NLS-
G 2 demonstrated a stronger suppressive effect than the wild-
type G 2 (Fig. 5 C). Wild-type, and NES- and NLS-fused G 2
were similarly expressed in HCT116 cells (Fig. 5 D). These re-
sults indicate that increased nuclear localization of G 2 correlates
with its suppressive effect on GR-induced transcriptional activity.
G  accumulates on GREs through GR 
in vivo
We, therefore, performed a chromatin immunoprecipitation
(ChIP) assay in COS7 cells that had a stably integrated MMTV
promoter in their genomic DNA. We expressed G 2 and GR in
these cells and detected the coprecipitated MMTV GREs by
the PCR with a specific primer pair (Fig. 6 A). G 2 was at-
tracted to GREs when the wild-type GR was coexpressed with
G 2, whereas G 2 was not precipitated with GREs in the pres-
Figure 5. Forced cytoplasmic localization of G 2 atten-
uates the suppressive effect of the wild-type G  on GR-
induced transactivation, whereas forced nuclear localiza-
tion enhances it. (A and B) EGFP-fused NES-G 2 and
NLS-G 2 are exclusively localized in the cytoplasm and
the nucleus, respectively, in HCT116 cells. HCT116 cells
were transfected with pEGFP-C1-NES-G 2- or pEGFP-C1-
NLS-G 2-expressing plasmid. The cells were fixed and
their confocal images were obtained. Representative
images are shown in A, whereas mean   SEM values of
signal intensities in the nucleus (black bars) and the cyto-
plasm (white bars) obtained from over 20 cells are shown
in B. (C) NES-G 2 loses the suppressive effect on GR
transactivation, whereas NLS-G 2 has a stronger inhibitory
effect than the wild-type G 2 on GR transactivation in
HCT116 cells. HCT116 cells were transfected with
pCDNA4His/MaxB-NES-G 2- or -NLS-G 2 together with
pRShGR , pMMTV-Luc, and pSV40- -Gal. Bars represent
mean   SEM values of the luciferase activity normalized
for  -galactosidase activity in the absence or presence
of 10
 6 M of dexamethasone. (*), P   0.01; n.s., not
significant, compared with the baseline. (D) G 2 wild-
type and its fusions with NES or NLS are similarly expressed
in HCT116 cells. HCT116 cells were transfected with
pCDNA4His/MaxB-G 2, -NES-G 2-, or -NLS-G 2. The
cells were lysed and the expression of wild-type, NES-,
and NLS-fused G 2 was examined in a Western blots
using anti-His antibody.
or -G 2, and the cells were fixed and their confocal images were obtained. Nuclei were also stained with DAPI. Representative images of EGFP-G 2 and -G 2
are respectively shown in C, whereas mean   SEM values of their signal intensities in the nucleus and the cytoplasm obtained from over 20 cells are shown
in D. (E and F) EGFP-G 2 translocated into the nucleus with DsRed2-GR in response to 10
 6 M of dexamethasone in HCT116 cells. HCT116 cells were
transfected with pEGFP-C1-G 2 and pDsRed2-GR . Confocal images of EGFP-G 2 and DsRed2-GR were obtained before and 30 min after the treatment
with 10
 6 M of dexamethasone. Representative images are shown in D, whereas mean   SEM values of signal intensities in the nucleus (black bars) and
the cytoplasm (white bars) obtained from over 20 cells is shown in E. (G) EGFP-G 2 and DsRed2-GR are colocalized at the plasma membrane in response
to somatostatin in HCT116 cells. HCT116 cells were transfected with pEGFP-C1-G 2, pDSRed2-GR , and G 2- and SSTR2-expressing plasmids. Confocal
images of EGFP-G 2 and DsRed2-GR were obtained before and 30 min after the treatment with 100 nM of somatostatin. Blue and orange arrows indicate
signals of EGFP-G 2, DsRed2-GR, which are localized at the plasma membrane, whereas yellow arrows indicate their colocalization.JCB • VOLUME 169 • NUMBER 6 • 2005 892
ence of GR( 262-404), indicating that G 2 was attracted to
GREs through physical interaction with the GR. In these cells,
overexpression of G 2 suppressed the transcriptional activity
of the chromatin-integrated MMTV promoter in a dexametha-
sone-dependent fashion (Fig. 6 B).
G 2 does not have intrinsic 
transcriptional activity but suppresses 
the AF-2–directed transcriptional 
activity of the GR
To explore the mechanism of the transcriptional regulation of
GR by G 2, we constructed a plasmid expressing the GAL4-
fused G 2 and examined its transcriptional activity on the
GAL4-responsive promoter-driven luciferase construct in
HCT116 cells (Fig. 6 C). As positive controls, we used GAL4-
fused VP16- and SMRT-expressing plasmids, which respec-
tively demonstrate transactivating or transrepressing activity
on this promoter (Nagy et al., 1997; Pazin et al., 1998). GAL4-
G 2 did not change the basal transcriptional activity of the
promoter at all, whereas GAL4-VP16 and -SMRT respectively
activated or suppressed it, indicating that G 2 does not have
intrinsic transcriptional activity.
We further examined the effect of G 2 on the transcrip-
tional activity of the two GR mutants GR( 77-261) and
(1-515) in HCT116 cells, which are respectively devoid of the
AF-1 and AF-2 domains (Fig. 6 D). G 2 suppressed the tran-
scriptional activity of GR( 77-261) similarly to its effect on
the wild-type GR, whereas it did not affect the transcriptional
activity of GR(1-515), indicating that G 2 acts on GR by sup-
pressing AF-2 but not AF-1.
Discussion
The WD-repeat proteins G 1, G 2, and Rack1 interacted with
the GR at the NH2-terminal region enclosed between amino ac-
ids 263 and 419; G 2 used blades 3–5 for this interaction. All
three proteins suppressed the transcriptional activity of the GR
on the glucocorticoid-responsive GRE-containing MMTV pro-
moter and endogenous G 1 and G 2 functioned as negative
regulators of glucocorticoid-induced stimulation of TAT enzy-
matic activity and Kv1.5 potassium channel mRNA expres-
sion. G 2 acted as a heterodimer with G , and the G /G 
complex, but not G i, was associated with the GR in vivo both
in the absence and presence of dexamethasone. Somatostatin
suppressed GR-induced expression of the Kv1.5 potassium
channel mRNA via activation of the G /G  heterodimer. G 
and G  were localized in the nucleus as well as in the cyto-
plasm/plasma membrane, and a fraction of G 2 and GR comi-
grated to the nucleus or the plasma membrane, respectively, in
response to dexamethasone or somatostatin. Forced sequestra-
tion of G 2 away from the nucleus attenuated its suppressive
effect on GR-induced transactivation. Furthermore, G 2 was
attracted to GREs through the GR and suppressed GR-induced
transcriptional activity by inhibiting the AF-2 domain.
Figure 6. G 2 is attracted to GREs and directly suppresses
GR-induced transactivation by inhibiting its AF-2 function.
(A) G 2 was attracted to the chromatin-integrated MMTV
GREs via interaction with GR in COS7 cells. COS7 cells,
which have genomically integrated MMTV-Luc, were
transfected with G 2-expressing plasmid and pRShGR 
or pRShGR ( 262-404). 24 h after addition of 10
 6 M
of dexamethasone, the cells were fixed and the ChIP
reaction was performed with anti-G  or control antibodies.
The portion of the MMTV promoter that contains two
GREs was amplified by PCR with a specific primer pair.
Two images obtained from separate gels were combined
to produce the Input gel image. (B) G 2 suppresses the
transcriptional activity of GR on the chromatin-integrated
MMTV promoter in COS7 cells. COS7 cells with genomi-
cally integrated MMTV-Luc, were transfected with the
indicated amounts of the G 2-expressing plasmid, together
with pRShGR  and pSV40- -Gal. Bars represent mean  
SEM values of the luciferase activity normalized for
 -galactosidase activity in the absence or presence of
10
 6 M of dexamethasone. (*), P   0.01, compared with
the baseline. (C) G 2 does not have intrinsic transcrip-
tional activity. HCT116 cells were transfected with increas-
ing amounts of GAL4 DBD-fused G 2-, SMRT-, or VP16-
expressing plasmid together with pGAL4-E1B-Luc and
pSV40- -Gal. Bars represent mean   SEM values of the
luciferase activity normalized for  -galactosidase activity.
(D) G 2 suppresses the AF2-directed transcriptional activ-
ity of GR, but not the AF-1–dependent transactivation in
HCT116 cells. HCT116 cells were transfected with G 2-
expressing plasmid, pMMTV-Luc, and pSV40- -Gal
together with pRShGR , pRShGR ( 77-261), or
pRShGR (1-515). Bars represent mean   SEM values of
the luciferase activity normalized for  -galactosidase activ-
ity in the absence or presence of 10
 6 M of dexametha-
sone. (*), P   0.01; n.s., not significant, compared with
the baseline.INTERACTION OF G PROTEIN   AND GR • KINO ET AL. 893
Components of the G protein system are presumably
strictly located at the inner surface of the plasma membrane at-
tached to it through the prenylated G  (Clapham and Neer,
1997). However, there are previously reported exceptions (Ka-
geyama et al., 1999; Jin et al., 2000; Zhang et al., 2001; Chen
et al., 2004); for instance, one of the G s, G 5 was reported in
the nucleus as well as in the cytoplasm and the membrane frac-
tion of the cell, and this protein translocated into the nucleus in
response to surface stimuli in neuronal cells (Zhang et al., 2001).
Similarly, G 3 was found in the cytoplasmic pool and moved to
the plasma membrane in response to stimulation of the  1 adren-
ergic receptor in rat cardiac cells (Kageyama et al., 1999). Fur-
thermore, endogenous G  replaced with the GFP-fusion form in
yeast cells was localized in the cytoplasm, in addition to the
plasma membrane, and changed localization in response to a
chemo-attractant (Jin et al., 2000). A distribution of G 1/G 2
similar to the one we found in our study was also reported re-
cently (Chen et al., 2004). In addition to these previous reports,
our results indicate that the localization of G  is more diffuse
than previously thought, being distributed in the cytoplasm and
the nucleus, as well as at the cytoplasmic surface of the plasma
membrane. EGFP-G 2 comigrated with DsRed2-GR into the
nucleus in response to dexamethasone, whereas it comigrated to
the plasma membrane with the GR after addition of somato-
statin. Together, these results indicate that G  can migrate be-
tween subcellular compartments, such as between the cytoplasm
and the nucleus or the plasma membrane, depending on the type
of stimuli and the responsive signaling molecules activating the
cell. Thus, it appears that cytoplasmic G  may function as a res-
ervoir pool, which supplies G proteins into various subcellular
compartments according to the needs of the cell (Fig. 7).
The G /G  complex down-regulated the transcriptional
activity of the GR in the nucleus. On the other hand, GR comi-
grated with G  to the plasma membrane, suggesting that
membrane-located GR may regulate the activity of the G /G 
heterodimer on its downstream effector molecules at the plasma
membrane. There are many reports indicating nongenomic or
cell membrane actions of glucocorticoids; indeed, glucocorti-
coids increase the Na
 -dependent uptake of glutamate, rapidly
inhibit release of arginine vasopressin in rat hypothalamus, and
transiently stimulate the activity of the Ca
2  channel (Sze and
Iqbal, 1994; Liu et al., 1995; Zhu et al., 1998; Falkenstein et al.,
2000). One of the steroid hormone receptors, the estrogen re-
ceptor was recently localized at the plasma membrane, and
shown to regulate cAMP production through interaction with
G i in neuronal cells (Navarro et al., 2003). Thus, it is possible
that G -associated GR might explain some of the nongenomic
effects of glucocorticoids at the plasma membrane.
In our experiments, 24-h incubation of cells with so-
matostatin suppressed GR-induced transcriptional activity by
stimulating the G /G  heterodimer, possibly by increasing the
fraction that can comigrate into the nucleus with the GR in re-
sponse to dexamethasone. The underlying mechanism of this
action is not understood, but it is possible that free G /G  het-
erodimers produced after stimulation with somatostatin might
have a greater chance to be associated with the GR, comigrate
with it into the nucleus and finally suppress GR-induced trans-
activation. Somatostatin has anti-inflammatory activity, and
glucocorticoids increase local production of somatostatin in in-
flamed tissues, a phenomenon that may explain part of their
anti-inflammatory actions (Karalis et al., 1994, 1995). Our re-
sults of the suppressive effect of somatostatin on GR-induced
transactivation complete a closed regulatory circuit between
glucocorticoids and somatostatin, with the ligand-activated GR
stimulating somatostatin and the GR-associated somatostatin-
stimulated G /G  complex suppressing the latter’s effect.
G  physically interacted with the GR as a heterodimer
with G  in the absence of dexamethasone, and addition of
dexamethasone further increased the association of the G /G 
complex with the GR. The ligand-free GR forms a multi-protein
complex with several heat shock proteins. In this complex, GR
is also associated with other molecules, such as protein 14-3-3,
Raf-1, and p53, which modulate GR-induced transcriptional ac-
tivity (Kino and Chrousos, 2002). The G /G  complex and
Rack1 should be added to these GR-associated molecules,
which suppress the transcriptional activity of the GR. Because
Rack1 plays an important role in the regulation of signaling
events induced by PKC, cAMP, and several growth factors and
cytokines (McCahill et al., 2002), it is possible that these sig-
naling cascades also regulate GR function through Rack1, as in
the case of G , where the upstream stimulus somatostatin sup-
presses GR-induced transcriptional activity.
G  together with G  was attracted to GREs through the
GR, inhibiting AF-2. G  did not have any intrinsic transrepres-
sive activity, and, hence, it is unlikely that it functions as an ac-
tive repressor by attracting inhibitory molecules/complexes,
such as, for instance, corepressors with histone deacetylase ac-
tivity (Jones and Shi, 2003). Rather, G /G  may act as a nega-
tive scaffold, similarly to Rack1, by binding to a critical portion
of the GR and/or other transcriptional intermediate molecules
that are attracted to the AF-2, blocking full activation of AF-2
and hence transcription stimulation by the ligand-bound GR.
Figure 7. Interactions between the glucocorticoid and GPCR signaling
systems at the level of the GR and the G /G  subunits. In response to
activation of a GPCR and the GR by their respective ligands, the G /G 
complex interacts with the GR and translocates with it into the cell nucleus
where it suppresses glucocorticoid-induced transactivation. The inactivated
G /G  complex, normally located under the plasma membrane, may
serve as an anchor to the nonligand-activated GR.JCB • VOLUME 169 • NUMBER 6 • 2005 894
Materials and methods
Plasmids
pLexA-GR (263–419) was constructed by inserting the corresponding
cDNA fragment of GR (263–419) into pLexA (CLONTECH Laboratories,
Inc.). pB42AD-G 1(1–340), -G 2(1–340), -G 2(1–143), -G 2(270–340),
-G 2(143–226), -G 2(55–226), -G 2(183–270), and -G 2(226–310)
were constructed by subcloning the corresponding cDNA fragments of
G 1 or G 2 into pB42AD (CLONTECH Laboratories, Inc.). pB42AD-
Rack1(1-317) and -Rack1(139-317) were gifts from D. Adam (University of
Kiel, Kiel, Germany). pOP8-LacZ was purchased from CLONTECH Labora-
tories, Inc. pCDNA4His/MaxB-G 1 and -G 2 were constructed by insert-
ing coding sequences of G 1 and G 2 into pCDNA4His/MaxB (Invitro-
gen). pEGFP-C1-G 2 and -G 2 were also produced by subcloning the
coding sequences of G 2 and G 2 into pEGFP-C1 (CLONTECH Laborato-
ries, Inc.). pCDNA4His/MaxB-NLS-G 2, -NES-G 2, or pEGFP-C1-NLS-G 2
and -NES-G 2 were constructed by inserting synthesized oligonucleotides
corresponding to the NLS (AELIPEPPKKKRKVELGTA) of the SV40 large T an-
tigen and the NES (NSNELALKLAGLDINKTE) of the human protein kinase in-
hibitor   into pCDNA4His/MaxB-G 2 and pEGFP-C1-G 2, respectively, at
the portion in front of their G 2 coding sequence (Rihs et al., 1991; Hender-
son and Eleftheriou, 2000). pCDNA3-Rack1 was a gift from D. Adams.
pDsRed2-GR  was constructed by inserting a coding sequence of the human
GR  into pDsRed2 (CLONTECH Laboratories, Inc.). pRShGR , pRShGR 
( 262–404), ( 77–261) and (1–515), and GAL-SMRT were all gifts from
R.M. Evans (Salk Institute, La Jolla, CA). pCMV6-SSTR2, which expresses the
human SSTR2, was a gift from S. Seino (University Kobe, Hyogo, Japan).
pMMTV-Luc, which has the luciferase gene under the control of the MMTV
promoter (which has four functional GREs) was donated from G.L. Hager
(National Cancer Institute, Bethesda, MD). pGAL4-E1B-Luc, which has the lu-
ciferase gene under the control of 4 GAL4 response elements, was a gift
from P.H. Driggers (Uniformed Services University of the Health Sciences,
Bethesda, MD). GAL4-VP16 was a gift from Y. Shi (Harvard Medical
School, Boston, MA). pSV40- -Gal was purchased from Promega.
Yeast two-hybrid screening and assay
The yeast two-hybrid screening was performed using GR(263-419) as a
bait in a human Jurkat cell cDNA library with the LexA system (CLON-
TECH Laboratories, Inc.). For a yeast two-hybrid assay, yeast strain
EGY48 (CLONTECH Laboratories, Inc.) was transformed with pOP8-LacZ,
pLexA-GR  (263–419), and indicated pB42AD-G 1, -G 2, and -Rack1
plasmids and  -galactosidase activity was measured in the cell suspension
as previously described (Kino and Chrousos, 2003). The  -galactosidase
activity was normalized for OD value at 600 nm. Fold induction was cal-
culated by the ratio of adjusted  -galactosidase values of cells trans-
formed with pLexA-derived bait plasmids versus pLexA in the presence of
the same prey plasmid.
Cell cultures, transient transfections, and reporter assays
Human colon carcinoma HCT116, African green monkey kidney COS7,
uterine cervical carcinoma HeLa, and rat pituitary GH3 cells were pur-
chased from the American Type Culture Collection and maintained in
MacCoy’s 5A or DME media supplemented with 10% FBS, 50 U of peni-
cillin, and 50  g/ml of streptomycin. Rat hepatoma HTC cells were pro-
vided by J.I. Webster (National Institute of Mental Health, Bethesda, MD)
and were cultured in DME with the same supplements. HCT116 and
COS7 cells do not contain functional GR, whereas HeLa, HTC, and GH3
cells express the fully active GR (Levitan et al., 1991; Thompson et al.,
1966; Kino et al., 2003c; Kino and Chrousos, 2003; Webster et al.,
2003; De Martino et al., 2004).
HCT116 cells were transfected as previously described (Kino et al.,
2003c). For the experiments using pMMTV-Luc or pGAL4-E1B-Luc as re-
porter plasmids, different amounts of G 1-, G 2-, G 2-, Rack1-, or GAL4-
fused molecule-expressing plasmids were cotransfected with 0.5  g/well
of pRShGR  (for pMMTV-Luc), 1.5  g/well of pMMTV-Luc or pGAL4-E1B-
Luc and 0.5  g/well of pSV40- -Gal. Empty vectors were used to main-
tain the same amounts of transfected DNA. 10
 6 M of dexamethasone
was added to 24 h after transfection. The cells were harvested after an ad-
ditional 24 h and luciferase and  -galactosidase assays were performed
as previously described (Kino et al., 1999).
Introduction of G 1 and G 2 siRNAs into HTC and GH3 cells, the TAT 
assay, and the RT-PCR
The rat G 1 and G 2 siRNAs (5 -AAGCUCUGGGAUGUCCGAG-
AAdTdT-3  and 5 -AACAUCUGCUCCAUCUAUAGUdTdT-3 , respec-
tively), which respectively target nucleotides 625–645 and 355–375 of
their coding regions, were produced by QIAGEN. The negative control
siRNA (5 -UUCUCCGAACGUGUCACGUdTdT-3 ) was also purchased
from QIAGEN.
HTC and GH3 cells were transfected with siRNAs by using the Nu-
cleofector System (Amaxa GmbH). In brief, 10
6 of HTC or GH3 cells were
resuspended in solution R and T (Amaxa GmbH), respectively, and were
mixed with 5  g of indicated siRNAs. The electricity was applied with the
Nucleofector Device (Amaxa GmbH) by using the protocol T-27 and T-20
for HTC and GH3 cells, respectively. We achieved nearly 80% transfec-
tion efficiencies in both cell lines with these combinations of solutions and
protocols. 24 h after plating these cells in the 24-well plates, the cells were
stimulated with 10
 6 M of dexamethasone and/or different concentrations
(0–100 nM) of somatostatin. After additional 24 h of incubation, cell ly-
sates for the TAT assay and Western blots, and total RNA for the RT-PCR
were harvested. TAT assays were performed as previously reported
(Thompson et al., 1966; Webster et al., 2003).
The reverse transcription reaction was performed as previously de-
scribed (De Martino et al., 2004). To detect mRNA levels of rat G 1,
G 2, Kv1.5 potassium channel and control rat acidic ribosomal phos-
phoprotein P0 (RPLP0), primer pairs (G 1: forward: 5 -CAGCAGACAAC-
CACGTTTAC-3 , reverse: 5 -CAGCCTGCATGTAGCATC-3 ; G 2: for-
ward: 5 -CTCATCATTTGGGACAGCTAC-3 , reverse: 5 -GTGATGATT-
TGGTTGTCGTC-3 ; Kv1.5 potassium channel: forward: 5 -CAACCTA-
GAAGGCTATCT-3, reverse: 5 -GTCGAAGAAGTATTCATTTC-3; RPLP0:
forward: 5 -GACATGCTGCTGGCCAATAAG-3 ; reverse: 5 -CAACATGT-
TCAGCAGTGTG-3 ) were used. The RT-PCR reaction, consisting of heat
activation of the Taq polymerase (10 min at 95 C) and the subsequent 60
PCR cycles (denaturing: 15 s at 95 C; annealing/extension: 1 min at
60 C) was performed in quadruplicate using the SYBR green PCR Master
Mix (Applied Biosystems) in an ABI PRIZM 7900 SDS lightcycler (Applied
Biosystems). Obtained CT (threshold cycle) values of G 1, G 2 and the
Kv1.5 potassium channel were normalized for those of RPLP0 and their rel-
ative mRNA expressions were demonstrated as fold induction of the base-
line. The dissociation curves of used primer pairs showed a single peak
and samples after PCR reactions had a single expected DNA band in an
agarose gel analysis (unpublished data).
Confocal microscopy analyses
HCT116 were cultured on poly-L-lysine–coated cover slides (for fixed cells)
or in Delta-T Culture Dishes (Bioptechs Inc.; for live cells) and transfected
and/or treated with the indicated plasmids/compounds. They were fixed
with 4% PFA, and were subsequently mounted on glass slides with the
Vectashield with DAPI (Vector Laboratories, Inc.), or were directly exam-
ined under the microscope. Emitted signals were recorded with the
LSM510 meta/axiovert 200M microscope (Carl Zeiss MicroImaging, Inc.)
stand at 19   1.0 C for fixed samples and at 37   0.5 C for samples cul-
tured in Delta-T Culture Dishes at the NICHD Microscopy and Imaging
Core (National Institute of Child Health and Human Development) with the
assistance of V. Schram. The plan-apochromat 63  oil (1.4 NA, DIC,
working distance   0.17 mm; Carl Zeiss MicroImaging, Inc.) objective
lens (Carl Zeiss MicroImaging, Inc.) was used with the lens immersion me-
dium (Immersol 518FF, n   1.518: Carl Zeiss MicroImaging, Inc.) for im-
age acquisition. Confocal images were built point by point by collecting
the intensities from the photo-multiplier tube using LSM 5 software version
3.2 (Carl Zeiss MicroImaging Inc.). Endogenous G  and G  were visual-
ized with anti-G  and -G 2 antibodies (Santa Cruz Biotechnology, Inc.)
followed by the FITC-labeled anti–rabbit IgG antibody (Santa Cruz Bio-
technology, Inc.). To demonstrate the specificity of anti-G  and -G 2 anti-
bodies, blocking peptides (Santa Cruz Biotechnology, Inc.) were co-
administered with them.
Regular coimmunoprecipitation assay, subcellular fractionation, 
and Western blots
HeLa cells were treated with 10
 6 M of dexamethasone or vehicle for 3 h.
Cell lysis and coimmunoprecipitation were carried as previously de-
scribed (Kino et al., 1999). Proteins were precipitated by anti-hGR  anti-
body or control rabbit IgG (Santa Cruz Biotechnology, Inc.) and the pro-
tein–antibody complexes were collected with protein Agarose A/G PLUS
(Santa Cruz Biotechnology, Inc.). After blotting on nitrocellulose mem-
branes, G i, G , and G  were detected by anti-G i, -G , or -G 2 anti-
bodies, respectively (Santa Cruz Biotechnology, Inc.). To evaluate endog-
enously expressed GR, G i, G , and G , 10% of cell lysates used in the
coimmunoprecipitation reaction were run on SDS-PAGE gels.
To compare endogenous levels of G  and G  residing in cytoplas-
mic, nuclear or membrane fractions, HCT116 cells were harvested and ho-
mogenated in buffer containing 50 mM Tris-HCl, pH 7.4, 25 mM KCl, 5INTERACTION OF G PROTEIN   AND GR • KINO ET AL. 895
mM MgCl2, 0.5 mM dithiothreitol, 0.25 M sucrose and 1 Tab/50 ml Com-
plete Tablet, and were centrifuged at 500 g for 5 min to obtain the whole
homogenate. All the procedures were performed at 4 C. The whole homog-
enates were then centrifuged at 2,000 g for 15 min to harvest the nuclear
fraction (pellet) and the supernatant was further centrifuged at 105,000 g
for 1 h to separate the cytoplasmic (supernatant) and membrane (pellet)
fractions. The nuclear and membrane fractions were washed once with the
same buffer. The samples (0.1  g of protein) were run on SDS-PAGE gels,
transferred to the nitrocellulose membranes, and G  and G  were detected
by reprobing the same membrane with anti-G  or -G 2 antibodies (Santa
Cruz Biotechnology, Inc.), respectively. The intracellular adhesion mole-
cule 1,  -tubulin and Oct1 were also respectively detected as positive con-
trols for the membrane, cytoplasmic and nuclear fractions by reprobing the
membrane with their specific antibodies (Santa Cruz Biotechnology, Inc.).
To evaluate the expression levels of wild-type and NES-/NLS-fused G 2,
plasmids expressing these molecules were transfected into HCT116 cells,
and whole homogenates were prepared as described above. Expressed
G -related proteins were then separated on a SDS-PAGE gel, blotted, and
visualized with anti-His antibody (Santa Cruz Biotechnology, Inc.).
ChIP assay
ChIP assay was performed in COS7/MMTV cells, which have the genom-
ically integrated MMTV-luciferase gene, (COS7/MMTV), using a ChIP kit
(Upstate Biotechnology) with minor modifications. COS7/MMTV cells
were transfected with control plasmid, pRShGR , or pRShGR ( 262-404)
in the presence of pCDNA4His/MaxB-G 2, and were exposed to either
10
 6 M of dexamethasone or vehicle for 5 h. The cells were then fixed,
DNA and bound proteins were cross-linked, and ChIP assays were per-
formed by coprecipitating the DNA–protein complexes with anti-GR  and
-G  antibodies or rabbit control IgG (Santa Cruz Biotechnology, Inc.), as
previously reported (De Martino et al., 2004). The promoter region  219
to  47 of the MMTV long terminal repeat was amplified from the pre-
pared DNA samples using a primer pair: 5 -AACCTTGCGGTTCCCAG-3 
and 5 -GCATTTACATAAGATTTGG-3 . Amplified products were then run
on a 3% agarose gel and visualized DNA bands were photographed.
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